883907--4/29/2009--CURRENT_TECHNOLOGY

related topics

{stock, price, share}

{product, market, service}

{acquisition, growth, future}

{control, financial, internal}

{product, candidate, development}

{product, liability, claim}

{property, intellectual, protect}

{customer, product, revenue}

{personnel, key, retain}

{loss, insurance, financial}

{operation, international, foreign}

{capital, credit, financial}

RISKS RELATED TO OUR BUSINESS Due to Our History of Operating Losses, We are Uncertain That We Will Be Able to Maintain Sufficient Cash to Accomplish Our Business Objectives. There is no certainty that our key project will be operationally successful or profitable. Disruptions in the Global Financial and Capital Markets May Impact Our Ability to Obtain Financing. We identified material weaknesses in our disclosure controls and procedures and our internal control over financial reporting. Our current business plan contemplates significant expansion, which we may be unable to manage. Our growth depends in part on the development, production and market acceptance of new products which we cannot assure will happen successfully. Any negative impact on the sales, licensing and marketing efforts of our products would adversely affect our business and results of operations. If our competitors or manufacturers develop products, systems or technologies that make our products less competitive or obsolete, our business would be harmed. We operate in new and rapidly evolving markets where rapid technological change can quickly make products, including those that we offer, obsolete. We are dependent on a number of third party network service providers, manufacturers and suppliers of our products and product components, the loss of any one of which could adversely impact our ability to service or supply our customers. We operate internationally, which subjects us to international regulation and business uncertainties that create additional risk for us. Certain of our products are subject to regulatory approval and if we fail to obtain FDA approval, we cannot market certain products in the United States. Our intellectual property rights are valuable, and any inability to protect them could reduce the value of our brand image and harm our business and our operating results. We risk exposing ourselves product liability claims, which could adversely affect our working capital, shareholders equity and profitability. TrichoGenesis products have historically been negatively perceived by the general public. We are dependent on our key personnel, and the loss of any could adversely affect our business. We will require additional capital in the future and we cannot assure you that capital will be available on reasonable terms, if at all, or on terms that would not cause substantial dilution to your stock holdings. We do not plan to pay dividends on our common stock. We currently have a limited trading market as there is limited liquidity on the OTC Bulletin Board which may impact your ability to sell your shares. Our common stock is subject to the penny stock rules which will limit the market for our common stock and increase the cost of sale because of additional broker compensation. There may be a greater risk of fraud on the NASD-OTC Bulletin Board.

Full 10-K form ▸

883907--4/29/2009--CURRENT_TECHNOLOGY_CORP